Deletion of the Men1 Gene Prevents Streptozotocin-Induced Hyperglycemia in Mice by Yang, Yuqing et al.
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2010, Article ID 876701, 11 pages
doi:10.1155/2010/876701
Research Article
Deletion of the Men1 GenePrevents Streptozotocin-Induced
HyperglycemiainMice
YuqingYang,1 Haoren Wang,1 andXianxinHua1,2
1Abramson Family Cancer Research Institute, Department of Cancer Biology, Abramson Cancer Center, University of Pennsylvania,
Philadelphia, PA 19104, USA
2Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Philadelphia, PA 19104, USA
Correspondence should be addressed to Xianxin Hua, huax@mail.med.upenn.edu
Received 16 September 2010; Revised 9 November 2010; Accepted 3 December 2010
Academic Editor: Anjan Kowluru
Copyright © 2010 Yuqing Yang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetes ultimately results from an inadequate number of functional beta cells in the islets of Langerhans. Enhancing proliferation
offunctionalendogenousbetacellstotreatdiabetesremainsunderexplored.Here,wereportthatexcisionofthe Men1 gene,whose
loss-of-function mutation leads to inherited multiple endocrine neoplasia type 1 (MEN1), rendered resistant to streptozotocin-
induced hyperglycemia in a tamoxifen-inducible and temporally controlled Men1 excision mouse model as well as in a tissue-
speciﬁc Men1 excision mouse model. Men1 excision prevented mice from streptozotocin-induced hyperglycemia mainly through
increasing the number of functional beta cells. BrdU incorporation by beta cells, islet size, and circulating insulin levels were
signiﬁcantly increased in Men1-excised mice. Membrane localization of glucose transporter 2 was largely preserved in Men1-
excised beta cells, but not in Men1-expressing beta cells. Our ﬁndings suggest that repression of menin, a protein encoded by
the Men1 gene, might be a valuable means to maintain or increase the number of functional endogenous beta cells to prevent or
ameliorate diabetes.
1.Introduction
Pancreatic beta cells are important for glucose sensing,
insulin production and secretion, and therefore, are crucial
for maintenance of blood glucose levels within the normal
range [1, 2]. Both type 1 diabetes (T1D) and type 2
diabetes (T2D) ultimately result from an inadequate number
of functional insulin-producing beta cells in the islets
of Langerhans. T1D arises from dramatic autoimmune-
induced beta-cell damage [1], while T2D develops due to
insulin resistance as well as a relatively insuﬃcient number
of beta cells [3]. Insulin production is eventually insuﬃcient
for maintaining normal blood glucose levels in T1D or
T2D,leadingtohyperglycemiaandsecondarycomplications,
including cardiovascular disease, kidney dysfunction, and
blindness [1, 3, 4]. While therapies through immunomodu-
lationorimprovinginsulinsensitivityhaveshownpromising
eﬀects on preventing or reversing hyperglycemia [5–8],
how to promote proliferation or regeneration of functional
endogenousbetacellstoboostthenumberoffunctionalbeta
cells needs to be further investigated. Only a handful of genes
have been shown to aﬀect development of hyperglycemia
in diabetes mouse models. For example, overexpression
of Igf-1 in pancreatic beta cells prevents streptozotocin-
(STZ-) induced diabetes [9]. Ablation of p27cip1/kip1,a
cyclin-dependent kinase inhibitor, increases the number of
beta cells and prevents development of hyperglycemia in
db/db mice [10]. Deletion of Lkb1, a tumor suppressor
activating AMP-activated protein kinase, promotes beta-cell
proliferation and prevents glucose intolerance in high-fat
diet-fed mice [11]. However, these genes have been shown
to regulate proliferation of multiple types of cells [12, 13].
It is desirable to assess genes that preferentially aﬀect beta-
cell proliferation/regeneration in order to prevent or treat
diabetes.
Menin is a nuclear protein encoded by the Men1 gene,
which is mutated in familial multiple endocrine neoplasia
type 1 (MEN1) patients [14]. Menin has been shown to
preferentially repress cell proliferation in endocrine tissues
including pancreatic beta cells [15, 16]. Although beta-cell2 Experimental Diabetes Research
proliferation and blood insulin levels are increased a long
time after Men1 is excised in beta cells [15, 17, 18], little is
known as to whether Men1 excision within a short time can
prevent development of hyperglycemia in diabetes mouse
models and its underlying mechanisms.
STZisaglucoseanalog,anditselectivelybindstoglucose
transporter 2 (GLUT2), the protein localized in the beta cell
membrane, and is transported into beta cells [19, 20]. STZ
inducesbetacelldamage,whichmimicsthelossoffunctional
beta cells observed in T1D and T2D [20–23]. In the present
study, we used a multiple low-dose streptozotocin- (MLD-
STZ-) induced diabetes mouse model and determined the
impactofMen1 excisiononSTZ-inducedhyperglycemia[19,
22]. We found that Men1 excision prevented STZ-induced
hyperglycemia, at least partly through promoting beta-cell
proliferation, and preserving the number of functional beta
cellsandcirculatinginsulinlevels.Theseﬁndingssuggestthat
menin is crucial for regulating beta-cell proliferation in vivo
and may perhaps be targeted for the prevention or treatment
of diabetes.
2.MaterialsandMethods
2.1. Mice. Men1l/l; Cre-ER mice were generated by cross-
ing mice with the ﬂoxed Men1 (Men1l/l, FVB/129Sv)
to mice harboring the Ubc9 promoter-driven Cre-ERT2
(129Sv/C57BL6J, a gift from Dr. Eric Brown) [17, 24].
Men1l/l mice, with exons 3 to 8 of Men1 ﬂanked by two
loxP sites, were kindly provided by Dr. Francis Collins.
Men1l/l;R I P - C r emice were generated by crossing ﬂoxed
Men1 mice with mice expressing Cre driven by the rat
insulin-2 promoter (RIP-Cre, TgN(ins2-cre)25Mgn, Jack-
son Laboratory) [15]. Only male mice were used for
the following experiments. The genotyping of mice was
performed by PCR using mouse tail DNA as templates. For
Men1:P 1 ,5  -CCCACATCCAGTCCCTCTTCAGCT-3 ;P 2 ,
5 -AAGGTACAGCAGAGGTCACAGAG-3 ;P 3 ,5  -GAC-
AGGATTGGGAATTCTCTTTT-3 .F o rCre-ERT2:f o r w a r d
(F), 5 -ACACCAAAATTTGCCTGCATTACCGG-3 ;r e v e r s e
(R), 5 -TTTCCATGAGTGAACGAACCTGGT-3 .F o rRip-
Cre:F ,5  -GCGGTCTGGCAGTAAAAACTATC-3 ;R ,5  -
GTGAAACAGCATTGCTGTCACTT-3 . All mouse experi-
ments were approved by the University Laboratory Animal
Resource and the University of Pennsylvania Committee on
Animal Care. The animal care was performed in accordance
with institutional guidelines.
2.2. Excision of the Floxed Men1 Locus Using Tamoxifen
(TAM). Men1l/l; Cre-ER and their littermate controls were
fed TAM (MP Biomedicals) at 200mg/kg of body weight per
day for two consecutive days, followed by one day oﬀ and
then for another two consecutive days [18].
2.3. STZ-Induced Hyperglycemia. Hyperglycemia was in-
duced by daily intraperitoneal (i.p.) injection of streptozo-
tocin (Sigma) at 40mg/kg of body weight per day for 5
consecutive days [22]. STZ working solution was freshly pre-
pared by dissolving STZ in 25mM sodium citrate solution
(pH 4.0) and immediately injected after each preparation.
B l o o dg l u c o s el e v e l sw e r em o n i t o r e du n t i l4w e e k sa f t e rt h e
last dose of STZ injections.
2.4. Physiological Measurements. Blood glucose levels were
assayed from tail vein blood by a glucose meter (OneTouch,
Lifescan). Blood serum insulin levels were measured by
ELISA using a mouse insulin kit (Crystal Chem). Serum
glucagon levels were determined by a RIA Kit (Linco).
2.5. Immunostaining. BrdU at 100mg/kg of body weight
was i.p. injected into mice 16 to 24 hours before they were
sacriﬁced.Twotothreeparaﬃn-embedded pancreassections
(5μm, at least 100μma p a r t )o fe a c hm o u s ea n dg e n o t y p e
were stained with aﬃnity-puriﬁed antibodies against menin
(1:500) [25], insulin (Abcam, 1:100), glucagon (Abcam,
1:100), BrdU (Accurate Chemical & Scientiﬁc, 1:150),
Pdx1 (Millipore, 1:500), and GLUT2 (Millipore, 1:200).
Secondary antibodies used were FITC (Abcam, 1:200) and
Alexa Fluor 546 (Invitrogen, 1:200). Images were captured
byaNikonEclipseE800ﬂuorescencemicroscopewithaCCD
digital camera. Total insulin staining area was quantiﬁed by
MetaMorph software (Molecular Devices).
2.6.StatisticalAnalysis. Resultsareexpressedasmean±SEM.
For a two-group comparison, unpaired Student’s t-test or
ranksumtestwasused.P valueslessthan.05wereconsidered
statistically signiﬁcant.
3. Results
3.1. Men1 Ablation Renders Mice Resistant to STZ-Induced
Hyperglycemia. To determine the impact of Men1 excision
on the development of diabetes, we evaluated whether
Men1 excision can prevent streptozotocin- (STZ-) induced
hyperglycemia using a conditional Men1 knockout mouse
model. To generate Men1l/l; Cre-ER mice, mice harboring
ﬂoxed Men1 were crossed with mice harboring an Ubc9
promoter-driven Cre-ERT2 transgene (Cre-ER)[ 17, 24]. The
resulting Men1l/+; Cre-ER mice and Men1l/+ mice were bred,
and Men1l/l; Cre-ER mice and their littermates (Men1l/l)
were used for the experiments. To check the eﬃciency of
Men1 excision in Men1l/l; Cre-ER mice, Men1l/l and Men1l/l;
Cre-ER mice were fed TAM, and menin levels in pancreatic
islets were determined by immunoﬂuorescence staining 4
weeks after TAM feeding. Immunostaining showed that in
the control Men1l/l mice, menin was preferentially expressed
in the nucleus of islet cells as compared with acinar cells
(Figure 1(a)). Menin was barely detectable in both islets and
acinar cells of the Men1l/l; Cre-ER mice, indicating that the
Men1 gene was eﬀectively excised in Men1l/l; Cre-ER mice
(Figure 1(b)).
We then administered multiple low-dose STZ (MLD-
STZ) to the control and Men1-excised mice to induce beta
cell damage and diabetes four weeks after Men1 excision
(Figure 1(c))[ 19, 22]. Immunoﬂuorescence staining showed
that Men1 was eﬀectively excised in the islets of Men1l/l;Experimental Diabetes Research 3
Cre-ER mice as compared with control mice 4 weeks after
STZ treatment (Figures 1(d) and 1(e)). In the control mice,
nonfasting blood glucose levels started to increase as early
as one week after STZ injections and ultimately reached
400mg/dL 4 weeks after STZ injections (Figure 1(f)). Men1-
excised mice, on the other hand, did not develop hyper-
glycemia during the whole period of study (Figure 1(f)),
demonstrating that Men1 ablation prevents STZ-induced
hyperglycemia.
3.2. Men1 Ablation Promotes Beta-Cell Proliferation and
Increases the Number of Functional Beta Cells. To determine
the underlying mechanisms whereby Men1 ablation prevents
STZ-induced hyperglycemia, we determined cell composi-
tion in islets, BrdU incorporation by beta cells, islet size, and
circulating insulin levels in control and Men1-excised mice 4
weeks after STZ injections.
Immunoﬂuorescence staining showed that both the
number and the percentage of insulin-producing beta cells
were signiﬁcantly reduced in islets of the control mice
(Figures2(a),2(c)-2(d)),ascomparedwiththeMen1-excised
mice (Figures 2(b)–2(d)). These ﬁndings suggest that Men1
excision either protected beta cells from STZ-induced beta
cell damage or increased the number of functional beta
cells. BrdU incorporation by beta cells, a marker for cell
proliferation, was signiﬁcantly higher in the Men1-excised
mice than the control mice (Figures 2(e)-2(g)), indicating
that Men1 excision increased the number of beta cells at least
partly through promoting beta-cell proliferation. Consistent
with an increase in the number of proliferating beta cells
after Men1 excision, insulin staining area was signiﬁcantly
larger in the Men1-excised mice (Figure 2(h)). Random
blood insulin levels, which were similar between the control
and Men1-excised mice before STZ treatment, dropped in
both groups after STZ injections (Figure 2(i)). However, it is
noteworthy that blood insulin level was reduced by ∼57% in
thecontrolMen1-expressingmice(before,1.12ng/mLversus
4wkafter,0.48ng/mL,Figure2(i)),whileitwasonlyreduced
by ∼34% in the Men1-excised mice (before, 1.01ng/mL
versus 4wk after, 0.67ng/mL, Figure 2(i)), suggesting that
there was less STZ-induced beta cell damage and deﬁcit
in insulin production and/or secretion in the Men1-exicsed
mice. Moreover, the blood insulin level was signiﬁcantly
higher in the Men1-excised mice than the control mice after
STZ injections (P<. 05, Figure 2(i)).
It is also noteworthy that the control mice, even with
severe hyperglycemia (∼400mg/dL, Figure 1(f)), did not
secrete more insulin to reduce high blood glucose levels
(4wk after STZ, 0.48ng/mL, Figure 2(i)), indicating a very
obvious deﬁcit in insulin production and/or secretion in
the control mice after STZ treatment. On the contrary,
even though the blood insulin level in the Men1-excised
mice was lower four weeks after than before STZ injections
(before STZ, 1.01ng/mL; 4wk after STZ, 0.67ng/mL, Fig-
ure 2(i)), the Men1-excised mice were normoglycemic (∼
150mg/dL, Figure 1(f)). These results indicate that insulin
produced/secretedbytheMen1-excisedmicewasadequateto
control their blood glucose levels within a normal range and
the nearly normal blood glucose levelsdid not trigger further
insulin secretion/production. Notably, we also found that
the ratio of blood insulin to glucose levels was signiﬁcantly
higher in the Men1-excised mice than the control Men1-
expressing mice (Figure 2(j)), suggesting that, after STZ
treatment, islet function and/or total insulin secretion by
islets in response to blood glucose stimulation was better
preserved in the Men1-excised mice, and that beta cells in
the Men1-excised mice were able to secrete more insulin
into blood circulation and keep blood glucose levels within
a relatively normal range. Taken together, these ﬁndings
strongly suggest that Men1 ablation prevents STZ-induced
hyperglycemia at least in part through promoting beta-
cell proliferation, resulting in the maintenance of a larger
numberoffunctionalbetacellsandhighercirculatinginsulin
concentrations.
It has been reported that the number of glucagon-
producing alpha cells is increased in diabetic state, and
knockdown of glucagon-receptor normalizes high glucose
levels in diabetic mice [26, 27]. Recent studies have also
shown that Men1-excised glucagon-producing alpha cells
can transdiﬀerentiate to insulin-producing beta cells in
normal mice, and alpha cells transdiﬀerentiate into beta
c e l l sm o r er a p i d l yw h e nb e t ac e l l sa r eu n d e rs e v e r es t r e s s
[28, 29]. Therefore, to determine whether Men1 ablation
prevents STZ-induced hyperglycemia through reducing the
number of alpha cells, the average number and percentage
of alpha cells in islets and circulating glucagon levels
were determined. We found that the number of glucagon-
secreting alpha cells per islet was similar in the control and
Men1-excised mice (Figure 3(a)). Although the percentage
of alpha cells was higher in control islets than Men1-excised
islets after STZ treatment (Figure 3(b)), which was likely
due to a low number of beta cells and consequently a
lower total number of cells in islets in the control mice, the
circulating glucagon levels were similar between the control
and Men1-excised mice (Figure 3(c)). This result suggests
that transdiﬀerentiation of alpha cells into beta cells was not
substantially aﬀected by Men1 excision 4 weeks after STZ
injections. Therefore, Men1 ablation likely prevents STZ-
induced hyperglycemia mainly through its impact on beta-
cell proliferation and increasing the number of functional
beta cells.
3.3. Men1 Ablation Speciﬁcally in Pancreatic Beta Cells
Prevents Development of STZ-Induced Hyperglycemia. To
determine whether Men1 excision, speciﬁcally in beta cells,
contributes to prevention of STZ-induced hyperglycemia,
Men1l/l; RIP-Cre mice were generated where Men1 was pref-
erentially excised in beta cells by the rat insulin promoter-
driven Cre recombinase [15]. Immunostaining showed that
menin protein level was signiﬁcantly reduced exclusively in
beta cells but not in adjacent acinar cells in the Men1l/l;
RIP-Cre mice at 12 weeks of age (Figure 4(b)), as compared
with the control Men1l/l mice (Figure 4(a)). These ﬁndings
suggest that Men1 was excised speciﬁcally in beta cells in
the Men1l/l; RIP-Cre mice. Islet size was increased in the
Men1l/l; RIP-Cre mice as compared with the control Men1l/l
mice (Figures 4(a) and 4(b)), which was consistent with the4 Experimental Diabetes Research
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Figure 1: Ablation of ﬂoxed Men1 prevents development of streptozotocin- (STZ-) induced hyperglycemia. (a) and (b) Immunostaining for
menin (red) and insulin (green), respectively, in pancreatic islets in mice fed TAM and without STZ treatment. Control Men1
l/l and Men1
l/l;
Cre-ER mice (n = 8 mice) were fed tamoxifen (TAM) at the age of 12 weeks at 200mg/kg of body weight per day for two consecutive
days, followed by one day oﬀ and then for another two consecutive days, as described in Section 2. Four weeks after the last dose of TAM
feeding, mice were sacriﬁced and pancreas sections of Men1
l/l (a) or Men1
l/l; Cre-ER mice (b) were immunostaed for menin and insulin. (c)
A schematic of experimental design. Control Men1
l/l (n = 18 mice) and Men1
l/l; Cre-ER mice (n = 2 1m i c e )w e r ef e dT A Ma tt h ea g eo f1 2
weeks. Four weeks after the last dose of TAM feeding, STZ was i.p. injected at 40mg/kg of body weight per day for 5 consecutive days. Blood
glucose levels were monitored till 4 weeks after STZ injections. (d) and (e) Immunostaining for menin (red) and insulin (green) in islets in
control Men1
l/l (d) and Men1
l/l; Cre-ER mice (e) that were treated with TAM and followed by STZ injections, as described in Figure 1(c).
The pancreata were collected 4 weeks after STZ treatment. (f) Non-fasting blood glucose levels before and until 4 weeks after STZ injections
(n = 18 to 21 mice). Scale bar, 25μm. ∗∗∗, P<. 001.
observations in the previous study [15]. On the other hand,
composition of beta cells and alpha cells in islets was similar
between the control and Men1l/l; RIP-Cre mice (Figures 4(c)
and 4(d)).
Men1l/l and Men1l/l; RIP-Cre mice at 12 weeks of age
were then injected with MLD-STZ, and blood glucose levels
were monitored up to 4 weeks after STZ injections (Fig-
ure4(e)).Men1 waseﬀectivelyexcisedinisletsoftheMen1l/l;
RIP-Cre mice as compared with the control mice (Figures
4(f) and 4(g)). Similar to what was observed in the TAM-
treated Men1l/l; Cre-ER mice, speciﬁc Men1 excision in beta
cellsintheMen1l/l;RIP-Cremicealsorenderedmiceresistant
to STZ-induced beta cell damage and hyperglycemia. Non-
fasting blood glucose levels in the control mice started
to increase as early as one week after STZ injections and
ultimately reached 450mg/dL 4 weeks after STZ injections
(Figure 4(h)). In contrast, Men1l/l; RIP-Cre mice did not
develophyperglycemiaduringthewholestudy(Figure4(h)).
Moreover, blood glucose levels in the Men1l/l; RIP-Cre
mice remained normal up to 8 weeks after STZ injections
(Figure 4(i)). Consistent with their normal blood glucose
levels 4 weeks after STZ injections, the percentage of insulin-
secreting beta cells in islets was signiﬁcantly higher in the
Men1l/l; RIP-Cre mice than the control mice (Figure 5(a)),Experimental Diabetes Research 5
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Figure 2: Ablation of ﬂoxed Men1 promotes beta-cell proliferation and increases beta cell number in STZ-treated mice. Study design was
described in Figure 1(c).C o n t r o lMen1
l/l (n = 18 mice) and Men1
l/l; Cre-ER mice (n = 21 mice) were fed TAM at age of 12 weeks. Four
weeks after the last dose of TAM feeding, STZ was i.p. injected at 40mg/kg of body weight per day for 5 consecutive days. Pancreata and
blood serum were collected from mice for further analysis, 4 weeks after STZ injections. (a-b) Immunostaining for insulin (green) and
g l u c a g o n( r e d )i ni s l e t si nc o n t r o lMen1
l/l (a) and Men1
l/l; Cre-ER mice (b). Nuclei were counterstained using DABI (blue). (c) Quantitation
of number of insulin-secreting beta cells in islets (n = 8 mice). (d) Quantitation of percentage of beta cells in islets (n = 8 mice). (e) and (f)
Immunostaining for BrdU (red) and insulin (green) in islets in control Men1
l/l (e) and Men1
l/l; Cre-ER mice (f). (g) Quantitation of BrdU
incorporation by beta cells (n = 8 mice). (h) Quantitation of insulin staining area (n = 8 mice). (i) Non-fasting serum insulin levels before
and 4 weeks after STZ injections (n = 18 to 21 mice). (j) Ratio of serum insulin (ng/mL) to blood glucose levels (mg/dL), multiplied by
10000. Scale bar, 25μm. ∗, P<. 05; ∗∗∗, P<. 001.6 Experimental Diabetes Research
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s u g g e s t i n gt h a tt h e r ew a sl e s sb e t ac e l ld a m a g ea n d / o rm o r e
functional beta cells preserved in the Men1l/l; RIP-Cre mice.
BrdUincorporationbybetacellswasalsosigniﬁcantlyhigher
in the Men1; RIP-Cre mice than the control mice (Figures
5(b)–5(d)), further conﬁrming that Men1 excision increased
the number of beta cells at least partly through promoting
beta-cell proliferation. Consistent with the observation that
beta-cell proliferation was increased after Men1 excision
(Figures 5(b)–5(d)), the insulin staining area was signiﬁ-
cantly larger in the Men1l/l; RIP-Cre mice than the control
mice (Figure 5(e)). Furthermore, random serum insulin
levels in the Men1l/l; RIP-Cre mice was signiﬁcantly higher
than the control mice after STZ injections (Figure 5(f)).
Moreover, there was no much diﬀerence in blood insulin
levels in the Men1l/l; RIP-Cre mice before and 4 weeks after
STZ injections (Figure 5(f)), strongly suggesting that there
waslessbetacelldamageandconsequentlyhighercirculating
insulin levels in the Men1l/l; RIP-Cre mice. These results also
support that Men1-speciﬁc excision in pancreatic beta cells
prevents STZ-induced hyperglycemia.
3.4. Men1 Ablation Preserves GLUT2 Membrane Localization
in Pancreatic Beta Cells in STZ-Treated Mice. Pdx-1 is a
crucialtranscriptionfactorforthedevelopmentandregener-
ation of beta cells in both normal and diabetic mice [30, 31].
GLUT2 is an important beta cell membrane protein respon-
sible for transporting glucose across beta cell membranes,
and it is involved in glucose sensing and glucose-stimulated
insulin secretion [32]. STZ binds to GLUT2 in beta cell
membranes and is transported into beta cells, and it induces
beta cell damage through several mechanisms including
damaginggenomicDNA[20].Inordertodeterminewhether
Men1 ablation prevents STZ-induced hyperglycemia partly
through its regulation on Pdx-1 and/or GLUT2, we sought
to detect expression or localization of Pdx-1 and GLUT2 in
beta cells in STZ-treated control and Men1-excised mice by
immunostaining.
We found that the number of Pdx-1 positive cells was
higher in Men1-excised islets than control islets (Figures
6(a) and 6(b)). However, given the fact that Pdx-1 protein
levels in individual beta cells did not appear substantially
diﬀerent between control and Men1-excised islets after STZ
injections, whether Men1 excision directly up-regulates Pdx-
1 expression still needs to be determined. Immunoﬂuores-
cence staining showed that GLUT2 was detectable in both
cell membranes and cytoplasm of beta cells in control and
Men1-excised mice without STZ treatment (Figures 6(c)
and 6(d)). Notably, after STZ injections, GLUT2 expression
was largely preserved in beta cell membranes in the Men1-
excised mice (Figure 6(f)), while it was barely detectable
in beta cell membranes in the control mice (Figure 6(e)).
These ﬁndings suggest that Men1 excision protects/preserves
GLUT2 membrane localization in beta cell membranes and
thus preserves the function of beta cells after STZ injections.
4. DiscussionsandConclusions
Previous studies have shown that beta-cell proliferation and
circulating insulin levels were increased in mice long after
Men1 excision [15, 17]. However, whether relatively acute
Men1 excision can prevent STZ-induced hyperglycemia and
its underlying mechanisms remains unclear. In the presentExperimental Diabetes Research 7
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Figure 4: Tissue speciﬁc ablation of ﬂoxed Men1 in beta cells increases resistance to STZ-induced hyperglycemia. (a–d) Control Men1
l/l
and Men1
l/l; RIP-Cre mice at the age of 12 weeks (n = 2 to 3 mice) without STZ treatment were sacriﬁced, and pancreata sections were
immunostainined for menin, insulin, or glucagon. (a-b) Immunostaining for menin (red) and insulin (green) in islets in control Men1
l/l (a)
and Men1
l/l; RIP-Cre mice (b). (c-d) Immunostaining for insulin (green) and glucagon (red) in islets in Men1
l/l (c) and Men1
l/l; RIP-Cre
mice (d). (e) A schematic of experimental design. Control Men1
l/l and Men1
l/l; RIP-Cre mice (n = 15 mice) at the age of 12 weeks were
injected with STZ at 40mg/kg of body weight per day for 5 consecutive days. Blood glucose levels were monitored, and mice were sacriﬁced
4 weeks after STZ injections. (f-g) Immunostaining for menin (red) and insulin (green) in islets in Men1
l/l (f) and Men1
l/l; RIP-Cre mice (g)
after STZ injections, as described in Figure 4(e). The pancreata were collected 4 weeks after STZ treatment. (h) Non-fasting blood glucose
levels before and 4 weeks after STZ injections (n = 12 to 15 mice). (i) Men1
l/l; RIP-Cre mice at the age of 12 weeks were injected with STZ
at 40mg/kg of body weight per day for 5 consecutive days. Blood glucose levels in Men1
l/l; RIP-Cre mice before and until 8 weeks after STZ
injections (n = 6 mice).8 Experimental Diabetes Research
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Figure 5: Tissue speciﬁc ablation of ﬂoxed Men1 promotes beta-cell proliferation and increases beta cell number in STZ-treated mice. Study
design was described in Figure 4(e). Control Men1
l/l and Men1
l/l; RIP-Cre mice (n = 15 mice) at the age of 12 weeks were injected with STZ
at 40mg/kg of body weight per day for 5 consecutive days. Pancreata and blood serum were collected from mice for further analysis, 4 weeks
after STZ injections. (a) Quantitation of percentage of insulin-secreting beta cells in islets (n = 4 to 7 mice). (b and c) Immunostaining for
BrdU (red) and insulin (green) in islets in Men1
l/l (b) and Men1
l/l; RIP-Cre mice (c). (d) Quantitation of BrdU incorporation by beta cells
(n = 4 to 7 mice). (e) Quantitation of insulin staining area (n = 4 to 7 mice). (f) Non-fasting serum insulin levels before and 4 weeks after
STZ injections (n = 12 to 15 mice). Scale bar, 25μm. ∗, P<. 05; ∗∗∗, P<. 001.
study, we employed an approach of temporally controlled
Men1 excision in multiple tissues as well as beta-cell speciﬁc
Men1 excision and found that Men1 excision prevented
development of hyperglycemia in STZ-treated mice. Our
results further showed that Men1 excision prevented devel-
opment of hyperglycemia mainly through increasing the
number of functional beta cells.
It was also noticed that, in contrast to the observation
that blood insulin level was reduced in the Men1l/l; Cre-ER
micesubjectedtoSTZtreatment4weeksafterMen1 excision,
blood insulin level was not decreased in the STZ-treated
Men1l/l;R I P - C r emice (Men1l/l; Cre-ER mice, Figure 2(i);
Men1l/l;R I P - C r emice, Figure 5(f)). The diﬀerence in the
time and duration of Men1 excision in these two groups of
micemightpartiallyexplainthediscrepancy.FortheMen1l/l;
Cre-ER mice, the Men1 gene was excised at age of 12 weeks
through TAM feeding and these mice were then challenged
with MLD-STZ 4 weeks after the last dose of TAM feeding
(Figure 1(c)). There were only 4 weeks (after the last dose of
TAM) for Men1-excised mice to replicate or regenerate more
functional beta cells before they were injected with STZ. In
contrast, in the Men1l/l;R I P - C r emice, the Men1 gene was
excised in beta cells during embryonic development, since
theratinsulinpromoter-drivenCre recombinaseisexpressed
and activated by insulin during embryonic stage. There were
about 12 weeks for Men1l/l;R I P -Cre mice to produce more
functional beta cells before they were challenged with STZ.
Duration of Men1 excision was much longer in the Men1l/l;
RIP-Cre mice than the TAM-treated Men1l/l; Cre-ER mice,
therefore it is likely that the Men1l/l;R I P - C r emice have more
functional beta cells than the TAM-treated Men1l/l; Cre-ER
mice before STZ injections and consequently higher number
of beta cells after STZ injections. As a result, blood insulin
level was not signiﬁcantly reduced in the Men1l/l;R I P - C r e
mice after STZ injections. In addition, it is also possible that
earlier Men1 excision during embryonic stage might lead to
somecompensationoradaptationofbetacellsintheMen1l/l;
RIP-Cre mice, which could also partially contribute to the
relative resistance of beta cells to STZ-induced damage and
reduction in blood insulin level.Experimental Diabetes Research 9
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of 12 weeks. Four weeks after the last dose of TAM feeding, STZ was i.p. injected at 40mg/kg of body weight per day for 5 consecutive days.
Pancreata were collected from mice 4 weeks after STZ injections. Nuclei were counterstained using DABI (blue). (c-d) Immunostaining for
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l/l; Cre-ER mice (n = 8 mice) were fed tamoxifen (TAM) at the age of 12 weeks at 200mg/kg of
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weeks after TAM feeding. (e-f) Immunostaining for GLUT2 and insulin in islets in control Men1
l/l (e) and Men1
l/l; Cre-ER mice (f) treated
with TAM and followed by STZ injections, as described in Figure 1(c).C o n t r o lMen1
l/l (n = 18 mice) and Men1
l/l; Cre-ER mice (n = 21
mice) were fed TAM at age of 12 weeks. Four weeks after the last dose of TAM feeding, STZ was i.p. injected at 40mg/kg of body weight per
day for 5 consecutive days. Pancreata were collected 4 weeks after STZ injections. Scale bar, 25μm.
Recent studies have shown that Men1-excised glucagon-
producing alpha cells transdiﬀerentiate to insulin-producing
beta cells in mice [28]. Moreover, transdiﬀerentiation from
alpha cells to beta cells occurs more rapidly when beta
cells are under severe stress [29]. However, our results
showed that the average number of alpha cells per islet and
blood glucagon level were similar between the control and
Men1-excised mice, suggesting that Men1 excision did not
substantially trigger transdiﬀerentiation of alpha cells to beta
cells 4 weeks after STZ injections. However, we cannot rule
out that Men1-excised alpha cells or other non-beta cells in
the pancreas can reprogram into insulin-secreting beta-cells
during the late stage of STZ-induced diabetes.
Our further analysis using immunostaining revealed that
there were more Pdx-1 positive cells in Men1-excised mice.
P d x - 1i sa ni m p o r t a n tt r a n s c r i p t i o nf a c t o ri nb e t a - c e l ld e v e l -
opment and growth [33, 34]. Our results showed that Pdx-
1 protein level in an individual beta-cell does not appear to
increasesigniﬁcantlyinMen1-excisedmiceascomparedwith
control mice, suggesting that Pdx-1 expression level might
be a marker for functional beta-cells after STZ injections,
and a reduced number of Pdx-1 positive cells in the control
mice may be a result of reduction in the total number
of functional beta-cells in those mice. Immunostaining
on pancreas sections also showed that GLUT2 localization
in beta-cell membranes after STZ injections were largely10 Experimental Diabetes Research
preserved in the Men1-excised mice as compared with
the control mice (Figures 6(e) and 6(f)). This result may
partly explain why Men1-excised mice showed normal blood
glucose levels and higher circulating insulin levels, since
GLUT2isinvolvedinglucosesensingandglucose-stimulated
insulin secretion [32]. On the other hand, because Men1
excision did not reduce membrane expression of GLUT2 in
beta-cells in mice without STZ treatments (Figures 6(c) and
6(d)), it is unlikely that relative resistance of Men1-excised
mice to STZ-induced beta-cell damage was due to changes in
membrane GLUT2 expression in beta-cells. Alternatively, we
could not rule out that Men1 excision improves the overall
function of beta-cells, rendering Men1-excised cells more
resistant to STZ-induced beta-cell damage.
It is also noteworthy that the RIP-Cre transgene, which
we used to speciﬁcally excise Men1 in beta-cells in Men1l/l;
RIP-Cre mice, has been reported to express in non-beta
cells, including the lung, spleen, testis, and brain [35],
especially in a group of poorly deﬁned neurons in the
hypothalamus (RipCre neurons) [36]. Knockout of insulin
receptor substrate 2 in this group of hypothalamic neu-
ronal population causes disruption in energy homeostasis,
increasesfoodintake,andleadstoobesityatalaterstage[36].
Because it has not been reported that tumors develop in the
hypothalamus in either MEN1 patients or Men1 knockout
mice, it is not clear whether menin represses proliferation
of RipCre neurons. Moreover, it is also unclear whether
Men1 excision in RipCre neurons aﬀects food intake or
other pathways involved in energy homeostasis or glucose
metabolism. Therefore, we could not rule out the possibility
that Men1 excision in non-beta cells may partly attribute to
improvement in glucose homeostasis in STZ-treated mice.
In conclusion, we have found that Men1 excision pre-
ventsSTZ-inducedhyperglycemiamainlythroughincreasing
the number of functional beta cells. BrdU incorporation by
beta cells, islet size, and circulating insulin levels were sig-
niﬁcantly increased in Men1-excised mice. Consistent with
our ﬁndings, menin is physiologically suppressed through
the prolactin signaling pathway in pancreatic beta cells in
pregnant mice to prevent gestational diabetes [37]. These
results suggest that menin might be targeted to promote
beta-cell proliferation and ameliorate diabetes. However,
since cell hyperplasia, insulinoma, and hyperinsulinemia
have been found in Men1 knockout mouse models or MEN1
patients [15, 38, 39], there is a justiﬁable concern that
disruption of menin aiming to promote beta-cell prolifer-
ation may lead to insulinoma, and permanent deletion or
inhibition of menin itself might not be a viable therapeutic
approach to treat diabetes. Instead, it might be possible to
promote beta-cell proliferation through reversibly inhibiting
menin or blocking the interaction between menin and its
partners. These approaches may retain menin’s tumor sup-
pressing functions, such as DNA repair [40], but transiently
dampen its ability to suppress beta-cell proliferation, thereby
increasing the number of functional endogenous beta cells
and ameliorating diabetes. In this regard, small molecule
compounds that target the interaction between menin and
its partners, if developed, could be useful for preventing or
treating diabetes.
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